title: Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis.
authors.forename: Maria Sole
authors.initials: MS
authors.lastname: Chimenti
authors.forename: Miriam
authors.initials: M
authors.lastname: Teoli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Di Stefani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Giunta
authors.forename: Maria
authors.initials: M
authors.lastname: Esposito
authors.forename: Roberto
authors.initials: R
authors.lastname: Perricone
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab; D012594:Scleroderma, Localized / Q000150:complications / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D000068800:Etanercept